148 related articles for article (PubMed ID: 38021449)
1. Cancer and the Vasopressin Gene: Radioimmunoassay Values and Commentary on Copeptin as a Plasma Marker.
North WG
Onco Targets Ther; 2023; 16():973-982. PubMed ID: 38021449
[TBL] [Abstract][Full Text] [Related]
2. Vasopressin gene related products are markers of human breast cancer.
North WG; Pai S; Friedmann A; Yu X; Fay M; Memoli V
Breast Cancer Res Treat; 1995 Jun; 34(3):229-35. PubMed ID: 7579487
[TBL] [Abstract][Full Text] [Related]
3. Targeting the neurophysin-related cell surface antigen on small cell lung cancer cells using a monoclonal antibody against the glycopeptide region (MAG-1) of provasopressin.
Keegan BP; Memoli VA; North WG
Mol Cancer Ther; 2002 Nov; 1(13):1153-9. PubMed ID: 12479696
[TBL] [Abstract][Full Text] [Related]
4. C-terminal provasopressin (copeptin) as a novel and prognostic marker in acute myocardial infarction: Leicester Acute Myocardial Infarction Peptide (LAMP) study.
Khan SQ; Dhillon OS; O'Brien RJ; Struck J; Quinn PA; Morgenthaler NG; Squire IB; Davies JE; Bergmann A; Ng LL
Circulation; 2007 Apr; 115(16):2103-10. PubMed ID: 17420344
[TBL] [Abstract][Full Text] [Related]
5. Assay for the measurement of copeptin, a stable peptide derived from the precursor of vasopressin.
Morgenthaler NG; Struck J; Alonso C; Bergmann A
Clin Chem; 2006 Jan; 52(1):112-9. PubMed ID: 16269513
[TBL] [Abstract][Full Text] [Related]
6. Changes in plasma copeptin, the c-terminal portion of arginine vasopressin during water deprivation and excess in healthy subjects.
Szinnai G; Morgenthaler NG; Berneis K; Struck J; Müller B; Keller U; Christ-Crain M
J Clin Endocrinol Metab; 2007 Oct; 92(10):3973-8. PubMed ID: 17635944
[TBL] [Abstract][Full Text] [Related]
7. Neuropeptide production by small cell carcinoma: vasopressin and oxytocin as plasma markers of disease.
North WG
J Clin Endocrinol Metab; 1991 Dec; 73(6):1316-20. PubMed ID: 1659583
[TBL] [Abstract][Full Text] [Related]
8. Comparison between copeptin and vasopressin in a population from the community and in people with chronic kidney disease.
Roussel R; Fezeu L; Marre M; Velho G; Fumeron F; Jungers P; Lantieri O; Balkau B; Bouby N; Bankir L; Bichet DG
J Clin Endocrinol Metab; 2014 Dec; 99(12):4656-63. PubMed ID: 25202818
[TBL] [Abstract][Full Text] [Related]
9. Plasma levels of copeptin in patients with coronary heart disease.
Chai SB; Hui YM; Li XM; Xiao Y; Tang CS
Heart Vessels; 2009 Mar; 24(2):79-83. PubMed ID: 19337789
[TBL] [Abstract][Full Text] [Related]
10. Plasma Apelin Concentrations in Patients With Polyuria-Polydipsia Syndrome.
Urwyler SA; Timper K; Fenske W; de Mota N; Blanchard A; Kühn F; Frech N; Arici B; Rutishauser J; Kopp P; Stettler C; Müller B; Katan M; Llorens-Cortes C; Christ-Crain M
J Clin Endocrinol Metab; 2016 May; 101(5):1917-23. PubMed ID: 26967692
[TBL] [Abstract][Full Text] [Related]
11. Copeptin, a surrogate marker for arginine vasopressin secretion, is positively associated with glucagon.
Lundegaard Asferg C; Bjørn Andersen U; Linneberg A; Goetze JP; Holst JJ; Jeppesen JL
Diabet Med; 2019 Nov; 36(11):1408-1411. PubMed ID: 30242900
[TBL] [Abstract][Full Text] [Related]
12. Elevated plasma copeptin levels identify the presence and severity of non-alcoholic fatty liver disease in obesity.
Barchetta I; Enhörning S; Cimini FA; Capoccia D; Chiappetta C; Di Cristofano C; Silecchia G; Leonetti F; Melander O; Cavallo MG
BMC Med; 2019 Apr; 17(1):85. PubMed ID: 31035998
[TBL] [Abstract][Full Text] [Related]
13. Differential Regulation of Plasma Copeptin Levels in Patients with Heart Failure: A Single-Center Prospective Study.
Iwashita N; Nara N; Sato R; Nakatogawa T; Kobayashi S; Zama S; Mita M; Hishinuma S; Shoji M
Tohoku J Exp Med; 2016 Jul; 239(3):213-21. PubMed ID: 27396431
[TBL] [Abstract][Full Text] [Related]
14. Copeptin, a surrogate marker of vasopressin, is associated with accelerated renal function decline in renal transplant recipients.
Meijer E; Bakker SJ; de Jong PE; Homan van der Heide JJ; van Son WJ; Struck J; Lems SP; Gansevoort RT
Transplantation; 2009 Aug; 88(4):561-7. PubMed ID: 19696640
[TBL] [Abstract][Full Text] [Related]
15. Gender and renal function influence plasma levels of copeptin in healthy individuals.
Bhandari SS; Loke I; Davies JE; Squire IB; Struck J; Ng LL
Clin Sci (Lond); 2009 Feb; 116(3):257-63. PubMed ID: 18647134
[TBL] [Abstract][Full Text] [Related]
16. The role of copeptin in patients with subarachnoid haemorrage.
Zissimopoulos A; Vogiatzaki T; Babatsikou F; Velissaratou M; Baloka L; Karathanos E; Pistola A; Christofis X; Iatrou X
Hell J Nucl Med; 2015; 18 Suppl 1():150. PubMed ID: 26665233
[TBL] [Abstract][Full Text] [Related]
17. Correlation of plasma copeptin and vasopressin concentrations in hypo-, iso-, and hyperosmolar States.
Balanescu S; Kopp P; Gaskill MB; Morgenthaler NG; Schindler C; Rutishauser J
J Clin Endocrinol Metab; 2011 Apr; 96(4):1046-52. PubMed ID: 21289257
[TBL] [Abstract][Full Text] [Related]
18. Isolation and partial characterization of two human neurophysins: their use in the development of specific radioimmunoassays.
North WG; LaRochelle FT; Melton J; Mills RC
J Clin Endocrinol Metab; 1980 Oct; 51(4):884-91. PubMed ID: 7419670
[TBL] [Abstract][Full Text] [Related]
19. Seasonal variation of vasopressin and its relevance for the winter peak of cardiometabolic disease: A pooled analysis of five cohorts.
Enhörning S; Melander O; Engström G; Elmståhl S; Lind L; Nilsson PM; Pihlsgård M; Timpka S
J Intern Med; 2022 Aug; 292(2):365-376. PubMed ID: 35340071
[TBL] [Abstract][Full Text] [Related]
20. Time course of copeptin during a model of experimental pain and hyperalgesia: A randomised volunteer crossover trial.
Mauermann E; Blum CA; Lurati Buse G; Bandschapp O; Ruppen W
Eur J Anaesthesiol; 2017 May; 34(5):306-314. PubMed ID: 28106611
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
